5. Progression during or after prior first line chemotherapy or chemoradiotherapy. Prior maintenance therapy, targeted therapy and immunotherapy are allowed. Prior use of Rovalpituzumab is allowed. Immunotherapy or targeted therapy will not be considered as second line therapy.